IFIH1 and interstitial lung disease: Despite aggressive treatment with immunosuppressants and corticosteroids, patients with concurrent anti-MDA5+ DM and RP-ILD have a high 6-month mortality rate of 50% to 70% after the development of symptoms (15, 16).